Vrillon, Agathe
Mouton-Liger, François
Martinet, Matthieu
Cognat, Emmanuel
Hourregue, Claire
Dumurgier, Julien
Bouaziz-Amar, Elodie
Brinkmalm, Ann
Blennow, Kaj
Zetterberg, Henrik
Hugon, Jacques
Paquet, Claire
Article History
Received: 29 January 2022
Accepted: 27 April 2022
First Online: 23 May 2022
Declarations
:
: This study was approved by the Bichat Hospital Ethics Committee of Paris Diderot University (N°10–037, 18/03/2010) and all the participants have given their written consent.
: Not applicable.
: KB has served as a consultant or at advisory boards for Abcam, Axon, Biogen, JOMDD/Shimadzu, Lilly, MagQu, Prothena, Roche Diagnostics, and Siemens Healthineers, and as data monitoring committee for Julius Clinical and Novartis. KB is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures. HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Alector, Annexon, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Pinteon Therapeutics, Red Abbey Labs, Passage Bio, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave; has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. CP is a member of the International Advisory Boards of Lilly; is a consultant for Fujirebio, Alzhois, Euroimmune, Ads Neuroscience, Roche, AgenT, and Gilead; and is involved as an investigator in several clinical trials for Roche, Esai, Lilly, Biogen, Astra-Zeneca, Lundbeck, and Neuroimmune. The other authors declare no competing interests.